Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Depreciation & Amortization (CF) (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $255000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 40.14% to $255000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 27.51% year-over-year, with the annual reading at $1.3 million for FY2025, 27.51% down from the prior year.
  • Depreciation & Amortization (CF) hit $255000.0 in Q4 2025 for Bolt Biotherapeutics, down from $290000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $467000.0 in Q1 2023 to a low of $255000.0 in Q4 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $389250.0 across 5 years, with a median of $417000.0 in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 169.31% in 2021 and later tumbled 40.14% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $361000.0 in 2021, then grew by 27.98% to $462000.0 in 2022, then rose by 1.08% to $467000.0 in 2023, then decreased by 8.78% to $426000.0 in 2024, then crashed by 40.14% to $255000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BOLT at $255000.0 in Q4 2025, $290000.0 in Q3 2025, and $347000.0 in Q2 2025.